Galeana RR, Carvajal GR, Minakata OFE

Language: Spanish
References: 18
Page: 41-45
PDF size: 148.51 Kb.

ABSTRACT

In this restrospective study, we evaluate the use of the botulinum toxin type A to treat refractory overactive bladder to the anticolinergic treatment. Material and methods: A total of 12 female patients were included in the study, between 45 – 60 years old, with diagnostic of non neurogenic refractory overactive bladder. They were trated with 300 UI of botulinum toxin type A injected intravesically, primary assessing voided urinary volumes, frequency and urinary incontinence episodes, before and after treatment. Results: There were significant improvement in the voided volumes, frequency, incontinence episodes, and in the quality of life of the patients with the botulinum toxine type A dosage used. Conclusions: The botulinum toxin type A is an efficient, safety and easy perform option to treatment of patients with non neurogenic refractory overactive bladder.

REFERENCES

1. Frenkl TL, Rackley RR. Injectable neuromodulatory agents: botulinum toxin therapy. Urologic Clinics of North America 2005; 32(1): 89-99.

2. Sutherland SE, Goldman HB. Treatment options for female urinary incontinence. Medical Clinics of North America 2004; 88(2): 345-66.

3. Schurch, Schmid, Stohrer. Treatment of neurogenic incontinence with botulinum toxin A. The New England Journal of Medicine 2000; 342(9): 665-66.

4. Wein, Alan J. Botulinum toxin in the management of lower urinary tract dysfunction: Contemporary update. The Journal of Urology 2005; 174(2): 611-612.

5. Abrams PH. Detrusor inestability and bladder outlet obstruction. Neurourol Urodynam 1998; 7: 403-428.

6. Schurch, Hauri, Rodic. Botulinum-A toxin as a treatment of detrusor-sphincter dyssynergia, a prospective study in 24 spinal cord injury patients. The journal of Urology 1996; 155(3): 1023-1029.

7. Phelan, Franks, Somogyi. Botulinum toxin urethral sphincter injection to restore bladder emptying in men and women with voiding dysfunction. The Journal of Urology 2001; 165(4): 1107-1110.

8. Schulte, Knispel. Botulinum A toxin in the treatment of neurogenic bladder in children. American Academy of Pediatrics, 2002; 110(2): 132-36.

9. Grazko, Polo, Jabbari. Botulinum toxin A for spasticity, muscle spasm, and rigidity. Neurology 1995; 45: 712.

10. Dykstra, Sidi, Scott. Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. The Journal of Urology 1988; 139: 919.

11. Dykstra, Sidi. Treatment of detrusor-sphincter dyssynergia with botulinum A toxin: a double blind study. Arch Phys Med Rehabil 1998; 71: 24.

12. Petit, Wiart, Gaujard. Botulinum A toxin treatment for detrusor-sphincter dyssynergia in spinal cord disease. Spinal Cord 1998; 36: 91.

13. Franks, Somogyi, Phelan. Botulinum toxin injection into the bladder wall decreases acetylcholine (ACH) and norepinephrine (NE) release: potential treatment for the overactive bladder. The Journal of Urology Suppl., 2001; 163: 42.

14. Schulte, Schobert, Stolze. Efficacy of botulinum A toxin in children with detrusor hyperrefexia due to myelomeningocele: preliminary results. Urology 2002; 59: 325-328.

15. Abrams, Feneley, Torrens. Standardization of terminology of lower tract function. Neurol Urodynam 2001; 7: 403.

16. Appell. Injectables for urethral incompetence. The Journal of Urology 1999; 8: 208-211.

17. Maraj GM, Miller R, Nathan S, O‘Sullivan C, Fowler CJ, Shah PJ, Lee MJ. Effects of botulinum toxin B on refractory detrusor overactivity: A randomized, double-blind, placebo controlled, crossover trial. The Journal of Urology 2005; 174(5): 1873-1877.

18. Chancellor MB. Urgency, botulinum toxin and how botulinum toxin can help urgency. The Journal of Urology 2005; 174(3): 818.